Posts Tagged ‘elderly’

Antipsychotic drugs double fatal pneumonia risk in elderly—drugs responsible for up to 1800 annual deaths in UK alone

Friday, August 27th, 2010

BBC News
August 27, 2010

The use of anti-psychotic drugs in the elderly doubles the risk of potentially fatal pneumonia, say Dutch researchers.

A study of almost 2,000 patients found the increased risk starts soon after treatment begins and concluded that patients should be closely monitored.

An expert review published in 2009 found the drugs are overused in many cases and are responsible for up to 1,800 deaths in the UK every year.

Ministers have said they want to see a significant cut in their use.

The latest research published in the Annals of Internal Medicine compared the health records of 258 over-65s with pneumonia with 1,686 patients without the infection.

Of those with pneumonia, a quarter died within a month.

When they looked at prescribed drugs, they found current use of anti-psychotics was associated with a roughly two-fold increase in the risk of pneumonia.

Those on the newer types of anti-psychotic drugs were slightly less likely to have the infection than those on the older class of drugs but were still at significant increased risk.

The risk was found to start soon after treatment and increased the higher the dose of drugs the patient was prescribed.

Read entire article here:  http://news.bbc.co.uk/2/hi/health/8599443.stm

« Return to news items


  • Share/Bookmark

Antidepressants Linked to Blindness in Older Adults

Tuesday, June 8th, 2010

Main Street
By Althea Chang
June 8, 2010

Antidepressant use could be linked to blindness in older adults, a recent study suggests.

Drugs that treat depression known as selective serotonin reuptake inhibitors, or SSRIs, caused an increased risk of developing cataracts in patients aged 65 or older, according to a study published in the journal Ophthalmology in June.

Researchers said cataracts may be more likely to develop in patients using this specific type of depression medication because serotonin receptors are found in the lens of the eye, according to MedPage Today.

Cataracts occur when the ocular lens gets cloudy and causes vision loss and even blindness. According to the World Health Organization, cataracts are responsible for 48% of age-related blindness cases worldwide.

While the elderly are generally more prone to developing cataracts than the population as a whole, researchers said they adjusted their study results to consider blood pressure, use of other medications and gender among the 200,000 people involved.

Read entire article:  http://www.mainstreet.com/article/family/family-health/antidepressants-linked-blindness

« Return to news items


  • Share/Bookmark

Wrongful Death Suit Claims Anti-depressant Led to Elderly Couple’s Murder-Suicide

Friday, May 28th, 2010

The West Virginia Record
By Lawrence Smith
May 28, 2010

RIPLEY — The murder-suicide of a Jackson County couple is at the center of a wrongful death, and product liability suit against New York pharmaceutical company.

Forest Laboratories and Forest Pharmaceuticals are named as co-defendants in a lawsuit filed in Jackson Circuit Court on April 30 by Robin J. Hall. In her six-count complaint, Hall, 49, a resident of Staats Mill, alleges Forest failed to alert both her father, and his physician of potentially dangerous side-effects of medication he was taking which resulted in him taking the life of his wife, then his own.

Located in New York, N.Y., Forest Laboratories is the parent company of Forest Pharmaceuticals based in St. Louis, Mo. Forest Pharmaceuticals handles the manufacture, sell and distribution of all Forest products in the United States.

In her suit, Hall says her father, Robert Raines, was prescribed Celexa by his doctor on April 24, 2008. Later that day, Raines purchased Celexa in 20 mg tablets.

Celexa is the brand name for Citalopram, a psychoactive drug in the class of selective serotonin reuptake inhibitors. It is used mostly for treatment of depression by altering a person’s serotonin levels.

Forest, Hall alleges, was aware Celexa caused an increased risk of suicidal behavior in people over 65, yet failed to conduct any further testing or investigation. Also, she alleges in its promotional materials, Forest failed to warn not only patients, but also physicians and pharmacists of that risk.

As early as Oct. 15, 2004, Forest was aware of the causality between SSRI drugs like Celexa and suicidal behavior in children. It was then, the U.S. Food and Drug Administration ordered Forest to put a “black box warning” on Celexa for anyone under the age of 24 about the potential risk of suicidal behavior.

Read entire:  http://www.wvrecord.com/news/227152-anti-depressant-led-to-elderly-couples-murder-suicide-jackson-suit-claims

« Return to news items


  • Share/Bookmark

AstraZeneca Fined $520 Million Over Illegal Marketing of its Antipsychotic Drug Seroquel

Thursday, April 29th, 2010

InjuryBoard.com
By Jane Akre
April 28, 2010

Pharmaceutical Giant, AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million after being fined by the federal government for illegally marketing the anti-psychotic drug, Seroquel.

Seroquel, also known as quetiapine fumarate, was approved by the FDA in 1997 to treat psychotic disorders. By October 2006, its use had expanded for use for bipolar depression and mania.

The Department of Justice alleges AstraZeneca illegally marketed Seroquel for uses other than those approved by the FDA such as Alzheimer’s disease, anger management, anxiety, ADD, dementia, depression, PTSD, mood disorders, among other uses considered “off-label.”

In 2008, Bloomberg reported that teenagers and the elderly were increasingly being given a class of anti-psychotic drugs not cleared by regulators. In adolescents, the medications are given for depression, autism and hyperactivity, and in the elderly for dementia and insomnia.

Half of Seroquel sales in 2006 were reportedly for off-label use.

In doing so, the company submitted false claims for payments from federal insurance programs including Medicaid, Medicare and TRICARE programs, Veterans Affairs, the Bureau of Prisons, and the Federal Employee Health Benefits Program.

Read entire article:  http://www.injuryboard.com/national-news/astrazeneca-fined-520-million-over-illegal-seroquel-marketing.aspx?googleid=280742

« Return to news items


  • Share/Bookmark

Johnson & Johnson Internal Documents Reveal Unsavory & Potentially Illegal Marketing of Antipsychotic drug Risperdal

Friday, March 12th, 2010

InjuryBoard.com
By Jim Lewis
March 12, 2010

The multi-billion dollar drug company, Johnson & Johnson (J&J), has come under fire for allegedly violating the rules in their marketing of Risperdal, an antipsychotic drug. Back in 1999, the Food and Drug Administration (FDA) told J&J that their marketing materials for geriatric patients overstated Risperdals benefits and minimized risks, according to Bloomberg.com. In 2000, an internal business plan strategized a way to increase Risperdals market share by marketing the benefits for elderly dementia, an unapproved use.

This was described as one of the more egregious examples of marketing drugs to vulnerable patients by Jerry Avorn, who works at the Harvard Medical School. He went on to say, seeing such clear evidence in black and white of the details of a campaign like this is still pretty upsetting.

J&Js marketing of Risperdal could be illegal since current law states that drug companies cannot promote a drug for uses other than those approved by the FDA. At the time this marketing and business plan was crafted, Risperdal was only approved for psychotic disorders like schizophrenia, not for dementia.

Read entire article:  http://virginiabeach.injuryboard.com/fda-and-prescription-drugs/johnson-johnson-internal-documents-reveal-unsavory-and-potentially-illegal-marketing-of-risperdal.aspx?googleid=279316

« Return to news items


  • Share/Bookmark

Internal documents show drug company marketed their antipsychotic Risperdal for unapproved usage on elderly & kids

Wednesday, March 10th, 2010

Bloomberg.com
By Margaret Cronin Fisk, Jef Feeley and David Voreacos
March 10, 2010

Johnson & Johnson made plans to reach $302 million in geriatric sales for its antipsychotic Risperdal just months after federal regulators said the company falsely claimed the drug was safe and effective with the elderly, according to internal documents.

The U.S. Food and Drug Administration told J&J in 1999 that its marketing materials for geriatric patients overstated Risperdal’s benefits and minimized risks. A J&J business plan for the next year called for increasing the drug’s market share for elderly dementia sales, an unapproved use, according to newly unsealed documents in a lawsuit by the state of Louisiana.

“The geriatric market represents Risperdal’s second wave of growth,” J&J officials wrote in the business plan. “The aging population will continue to drive market growth well into the next century.”

Louisiana officials cited the document and dozens of other internal J&J files in its lawsuit claiming the company marketed Risperdal to the elderly and children for unapproved uses. Professor Jerry Avorn of Harvard Medical School, who isn’t involved in the case, called the papers “one of the more egregious examples” of marketing drugs to vulnerable patients.

“By 2010, most grownups in medicine know that drug companies resort to unsavory practices to promote drugs, but seeing such clear evidence in black and white of the details of a campaign like this is still pretty upsetting,” Avorn said.

Read entire article:  http://www.bloomberg.com/apps/news?pid=20601109&sid=ag4Ya8UOIob0&pos=13

« Return to news items


  • Share/Bookmark

Think They Don’t Electroshock People Anymore? Think Again–Even toddlers and pregnant women are being shocked

Sunday, January 24th, 2010

By Dr. John Breeding, author of The Wildest Colts Make the Best Horses

child close-upAsk the average person about the use of electroshock treatment in today’s society and 9 out of 10 will respond, “They still shock people?”

They do. It’s estimated that more than 100,000 Americans are electroshocked each year; half are 60 and older, and two-thirds are women. In Australia, it was recently revealed that psychiatrists had electroshocked 55 toddlers age four and younger. In the UK, three year olds have been brutalized with it. And one of the country’s leading mental health “patients’ rights” groups—the National Alliance of Mental Illness (NAMI)—recently endorsed the use of electroshock on pregnant women. One would wonder why a patients’ rights group would endorse such an obviously harmful procedure if not for the fact that the group has recently been exposed as a major front for the psycho/pharmaceutical industry.

The FDA reports pregnant women miscarrying following ECT, while studies show that in addition to the risk of death, the fetus can suffer malnutrition, dehydration and violent injury. Electroshocking children, pregnant women and the unborn is tantamount to torture and should not only be banned but those administering it prosecuted.

Given the factual truths of sending up to 360 volts of electricity searing through the brain – the obvious question is why the “treatment” has not gone by the wayside like its psychiatric sister treatments during the 1940s and 1950s, insulin coma shock and lobotomy.

Electroshock was indeed challenged, and its low point pretty much coincided with the release in 1975 of the Academy Award-winning film version of Ken Kesey’s One Flew Over the Cuckoo’s Nest and Jack Nicholson’s portrayal of the feisty Randle Patrick McMurphy. The horrible scene of his undergoing “unmodified” shock treatment, i.e., without anesthetic and muscle-paralyzing drugs, along with his reduction to a vegetative state was seared in the public’s mind. This, together with public exposure of the shameful state of psychiatric institutions, certainly gave electroshock treatment a bad name—so much so that the treatment was renamed Electroconvulsive Therapy (ECT). The bad publicity caused its use in public institutions to fall sharply, and its overall use was also considerably diminished. It would be naïve, however, to think that this curtailment was strictly due to increased public awareness about the brutalities of the procedure. The advent of neuroleptics (nerve-seizing drugs) was perhaps the major factor in this development. The indiscriminate use of these drugs replaced the indiscriminate use of ECT as the primary means of subduing and pacifying inmates who resisted incarceration and wouldn’t cooperate.

In the last two decades, however, electroshock has made a comeback.

Most electroshock is insurance-covered. ECT specialists on average have incomes twice that of other psychiatrists. The cost for inpatient ECT ranges from $50,000 to $75,000 per series (usually 8 to 12 individual sessions). Electroshock is a multibillion-dollar-a-year industry—yet its damaging effects are well known to those who endorse it.

Max Fink, a professor of psychiatry and the “Grandfather of American ECT” believed the “therapeutic” effect from ECT is produced by brain dysfunction and damage. “Effects on memory, common in ECT, come in two flavors,” wrote Fink in Psychiatric Times in 2006. “Delirium is common with each seizure and is well documented by immediate measurable changes in brain chemistry and physiology” and “the second complaint is of a persistent loss of personal memories…They do not recall the names of their children, family holidays, or personal events….Their complaints cast a public shadow on ECT practice.”

The Procedure

Electroshock is a psychiatric procedure that involves the production of a grand mal convulsion, similar to an epileptic seizure, by passing from 70 to upwards of 600 volts of electric current through the brain for one-half second to four seconds. Before application, ECT subjects are typically given anesthetic, tranquilizing and muscle-paralyzing drugs to reduce fear, pain, and the risk (from violent muscle spasms) of fractured bones (particularly of the spine, a common occurrence in the early history of ECT before the introduction, in the mid-1950s, of the muscle-paralyzing drug succinylcholine [Anectine]). The ECT-induced convulsion usually lasts from thirty to sixty seconds and may immediately produce disorienting, painful, and even life-threatening complications, such as apnea (temporary suspension of breathing) and cardiac arrest. The convulsion is followed by a period of unconsciousness of several minutes’ duration. Electroshock is usually administered in hospitals because they are equipped to handle emergency situations that often develop during or soon after an ECT session.

Brain Damage

The brain naturally operates in millivolts of electricity, and ECT administers on average between 150 and 400 volts of electricity to the brain, a force sufficient to induce a grand mal seizure, rupture the protective blood-brain barrier and incite glutamate toxicity (glutamate is a powerful neurotransmitter released by nerve cells in the brain and is responsible for sending signals between nerve cells. In glutamate toxicity there is too much glutamate that leads to over-excitation of the receiving nerve cell, which can cause cell damage and/or death). It is prima-facie, common sense obvious fact that ECT causes brain damage. After all, the rest of medicine, as well as the building trades, do their best to prevent people from being hurt or killed by electrical shock. People with epilepsy are given anticonvulsant drugs to prevent seizures because they are known to damage the brain. The Electroshock Quotationary, a collection of quotations, excerpts, and essays about the history and nature of electroshock, by shock survivor Leonard Roy Frank, includes the testimony of Peter Sterling, a University of Pennsylvania neuroscience professor, describing the nature of ECT-caused brain damage, dated May 31, 2001, to the New York Assembly Standing Committee on Mental Health at a public hearing on ECT.

Sterling affirms the obvious: that massive amounts of electricity directly into the brain cause profound damage.

Lack of Efficacy

Not only does electroshock directly violate the Hippocratic oath to do no harm, the practice has never been proven effective. There are no lasting beneficial effects of electroshock; sham-electroshock (anesthesia but no electroshock) has the same short-term outcomes as electroshock (Ross, 2006). Even leading shock researcher and advocate Harold Sackeim now provides a proof. In an article from 2001, he and his colleagues conclude, “Our study indicates that without active treatment, virtually all remitted patients relapse within 6 months of stopping ECT.” (Italics mine)

The FDA

The battle against electroshock has been ongoing since its advent. The two recent chronicles by electroshock survivor activist leaders, Leonard Roy Frank (The Electroshock Quotationary) and Linda Andre (Doctors of Deception), tell the story best. Just now, the fight has centered on the FDA review of the “efficacy and safety” of ECT machines.

Many activists, including myself, have submitted testimony urging the FDA NOT to reclassify these devices from Class III (high risk) to Class II (low risk). I have worked with scores of electroshock survivors, and I can tell you the damage is consistent and terrible. I can also tell you as a psychologist that there are methods so much gentler, safer and more effective to help people with depression.

A Repackaged Product

The reason for electroshock’s endurance and resurgence is best described by Linda Andre, shock survivor and leader of the Committee for Truth in Psychiatry, in her masterful new work, Doctors of Deception: What They Don’t Want You to Know About Shock Treatment—it is simply the triumph of public relations over science. A concerted PR campaign has allowed electroshock to continue despite clear scientific evidence of its dismal and tragic record on safety and efficacy.

The industry repackaged the product to keep it selling. They touted a “newer and safer ECT,” bragging about improved equipment and the introduction of anesthesia and muscle paralysants, which actually came on the market in the 1950s. While the muscle paralysants greatly reduced the risk of broken bones from unrestrained convulsions, there was no lessening of permanent damage to the brain caused by the electroshocks. The drugs made the procedure appear much more benign because they suppressed the body’s natural, violent reaction to a grand mal convulsion. However, as Doug Cameron (1994) and other researchers have shown, the new machines, because they are more powerful than ever are capable of releasing greater amounts of electricity into the brain thus causing more damage than the older devices.

With the newer technique modifications there is also an added risk. The drugs used to prevent bone complications raise the seizure threshold so that more electrical current is required to induce the convulsion, which in turn increases brain damage. Moreover, whereas ECT specialists formerly tried to induce seizures with minimal current, they commonly use suprathreshold amounts in the belief that they are more effective. Again, the more current, the more brain damage. Proponents, and the public, have missed the point that the supposed “effectiveness” of ECT is in direct ratio to the amount of brain damage it causes.

In addition to the propaganda effect and the financial incentives, there is a less well-considered reason for ECT’s popularity among psychiatrists. Although electroshock is often described as psychiatry’s “treatment of last resort,” it is actually psychiatry’s “treatment of next resort.” Next resort after psychiatric drugs, which are the main “treatment”—a treatment whose lack of effectiveness and lack of safety are well documented. Like ECT, these drugs can damage and disable the brain. Like ECT, they can cause a fully justified resentment that goes with the experience of having been betrayed by one’s supposed helpers.

Activist and electroshock survivor Leonard Roy Frank’s recent letter to the FDA in regards to their review of ECT devices is one of the best. I end this blog article with his conclusion:

As a destroyer of memories and thoughts, electroshock is a direct, violent assault on these hallmarks of American liberty: freedom of conscience, freedom of belief, freedom of thought, freedom of religion, freedom of speech, freedom from assault, and freedom from cruel and unusual punishment. Tens of thousands of people every year in the United States are deceived or coerced into undergoing electroshock. The FDA should do everything in its power to discourage the use of electroshock by:

  • keeping ECT’s Class III, high-risk rating;
  • insisting that electroshock psychiatrists, manufacturers of ECT devices, and executives and administrators in hospitals where ECT is administered, substantiate with scientific proof their claims that the procedure is “safe and effective”;
  • and calling upon the Congress and the Department of Justice to investigate the fraudulent and coercive use of this cruel and inhuman procedure.

Despite the evidence of grievous harm and failure to help, electroshock’s proponents rave on; as an example, an electroshock psychiatrist told Washington Post reporter Sandra Boodman in 1996, that, “ECT is one of God’s gifts to mankind. There is nothing like it, nothing equal to it in efficacy or safety in all of psychiatry.”

Given that ECT causes brain damage, memory loss, and other serious cognitive impairment, electroshock serves to cover up and impede any potential malpractice or personal injury litigation. It generally takes years for a shock survivor to recover enough to figure out what has happened to them, and most states have a statute of limitations (usually one or two years) on medical malpractice and personal injury suits. As a result, electroshock survivors are effectively prevented from pursuing litigation against those who harmed them, making electroshock psychiatrists almost malpractice-proof.


John Breeding, Ph.D. has been a counseling psychologist in Austin, Texas for 25 years.
He is an outspoken critic of electroshock treatment and has testified against its use before legislative bodies on numerous occasions. Dr. Breeding is also the director of Texans For Safe Education, a citizens group dedicated to challenging the ever-increasing role of psychiatric drugs in schools. He is the author of numerous articles and four books including:
The Wildest Colts Make the Best Horses and True Nature and Great Misunderstandings.

For more information on the damage caused by ECT, visit www.endofshock.com

References

Ayd Jr., F.T. (November-December 1963). “Guest editorial: Ugo Cerletti, M.D. (1877-1963),” Psychosomatics, Vol. 4, pp. A-6 – A-7.

Boodman, S.G. (September 24, 1996). “Shock therapy: It’s back,” Washington Post (Health Section), pp. 14-20.

Frank, Leonard Roy, The Electroshock Quotationary, June 2006, www.endofshock.com/102C_ECT.PDF.

Andre, Linda, Doctors of Deception, www.doctorsofdeception.com.

Kalinowsky, L.B. (1988). Quoted in R. Abrams, “Interview with Lothar Kalinowsky, M.D.,” Convulsive Therapy, Vol. 4.

Ross, C.A. (Spring 2006). “The sham ECT literature: Implications for consent to ECT,” Ethical Human Psychology and Psychiatry, Vol. 8.

Sackeim, H.A. et al. (March 14, 2001). “Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy,” Journal of the American Medical Association.

Sackeim, H.A. (2001). “Memory loss: From polarization to reconciliation,” Journal of ECT, vol. 17, no. 3, p. 229. Sackeim, H.A., Prudic, J. et al. (January 2007). “The cognitive effects of electroconvulsive therapy in community settings,” Neuropsychopharmacology, Vol. 32, pp. 244-254.

RETURN TO BLOGS PAGE


  • Share/Bookmark

Report finds nearly 2,000 elderly patients killed each year by anti-psychotic drugs

Thursday, November 12th, 2009

Owen Bowcott
Guardian.co.uk
November 12, 2009

As many as many as 144,000 people suffering from dementia are being given anti-psychotic drugs unnecessarily, according to a review ordered by the Department of Health.

Excessive use of the medication causes an estimated 1,800 deaths and almost as many strokes among older people every year, the study revealed.

The care services minister, Phil Hope, accepted all the recommendations in the review and promised a fundamental change in the treatment of those suffering from dementia.

The numbers being given “chemical restraints” will be reduced, extra training will be given to nursing home staff, more psychological therapies are to be made available and a national clinical director for dementia will be appointed.

The author of the study, Sube Banerjee, professor of mental health and ageing at the institute of psychiatry at King’s College London, said that as few as 36,000 patients were benefiting from the use of anti-psychotic drugs, but their use was widespread and usually unquestioned.

Read entire article: http://www.guardian.co.uk/society/2009/nov/12/anti-psychotic-drugs-kill-dementia-patients

« Return to news items


  • Share/Bookmark

Rampant illegal psychiatric drugging of elderly/nursing home patients: 1,200 violations involving 2,900 patients

Tuesday, October 27th, 2009

Sam Roe
Chicago Tribune
October 27, 2009

Frail and vulnerable residents of nursing homes throughout Illinois are being dosed with powerful psychotropic drugs, leading to tremors, dangerous lethargy and a higher risk of harmful falls or even death, a Tribune investigation has found.

Thousands of elderly and disabled people have been affected, many of them drugged without their consent or without a legitimate psychiatric diagnosis that would justify treatment, state and federal inspection reports show.

Lloyd Berkley, 74, was in a nursing home near Peoria for less than a day before staff members held him down and injected him with a large amount of an antipsychotic drug, according to a state citation. A few hours later he fell, suffering a fatal head injury.

One woman was given a psychotropic drug partly because she refused to wear a bra. Nursing home staff administered an antipsychotic medication to an 87-year-old man because he was “easily annoyed.”

In all, the Tribune identified 1,200 violations at Illinois nursing homes involving psychotropic medications since 2001. Those infractions affected 2,900 patients.

Read entire article: http://www.chicagotribune.com/health/chi-nursing-home1-psychotropics-oct27,0,4539632.story

« Return to news items


  • Share/Bookmark

Scandalous abuse of the elderly prescribed antipsychotics in hospital exposed

Wednesday, October 7th, 2009

Rebecca Smith
The Daily Telegraph
October 7, 2009

Three quarters of nurses have seen people with dementia in general wards in hospital prescribed antipsychotic drugs that are known to double the risk of death and triple the risk of a stroke in these patients, research has shown.

It is the first time the scale of the abuse in hospital wards is exposed, following warnings that 100,000 dementia patients in care homes are prescribed the drugs leading to the deaths of 23,000 a year.

Ten leading charities, carers groups and experts have written to The Daily Telegraph saying: “We cannot stand by while this scandalous abuse of vulnerable citizens continues.”

Neil Hunt, Chief Executive of Alzheimer’s Society said: “The massive over prescription of antipsychotics to people with dementia is an abuse of human rights, causing serious side effects and increasing risk of death.

Read entire article: http://www.telegraph.co.uk/health/healthnews/6264962/Scandalous-abuse-of-the-elderly-prescribed-antipsychotics-in-hospital-exposed.html

« Return to news items


  • Share/Bookmark